Throughout the last three months, 19 analysts have evaluated Veeva Systems VEEV, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 6 | 6 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 3 | 5 | 5 | 1 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $224.89, a high estimate of $260.00, and a low estimate of $173.00. Highlighting a 4.95% decrease, the current average has fallen from the previous average price target of $236.61.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Veeva Systems among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Karl Keirstead | UBS | Raises | Neutral | $215.00 | $185.00 |
| Jack Wallace | Guggenheim | Raises | Buy | $233.00 | $211.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $260.00 | $260.00 |
| Brent Bracelin | Piper Sandler | Lowers | Overweight | $225.00 | $235.00 |
| David Larsen | BTIG | Announces | Buy | $240.00 | - |
| Rishi Jaluria | RBC Capital | Maintains | Outperform | $250.00 | $250.00 |
| Jailendra Singh | Truist Securities | Lowers | Hold | $197.00 | $203.00 |
| Tyler Radke | Citigroup | Lowers | Buy | $256.00 | $274.00 |
| Karl Keirstead | UBS | Lowers | Neutral | $185.00 | $235.00 |
| Saket Kalia | Barclays | Lowers | Overweight | $220.00 | $245.00 |
| David Hynes | Canaccord Genuity | Lowers | Hold | $210.00 | $220.00 |
| David Grossman | Stifel | Lowers | Buy | $210.00 | $250.00 |
| Kirk Materne | Evercore ISI Group | Lowers | In-Line | $200.00 | $230.00 |
| Craig Hettenbach | Morgan Stanley | Lowers | Underweight | $173.00 | $210.00 |
| Joe Vruwink | Baird | Lowers | Outperform | $245.00 | $255.00 |
| Brad Sills | B of A Securities | Lowers | Neutral | $204.00 | $240.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $260.00 | $260.00 |
| Brent Bracelin | Piper Sandler | Lowers | Overweight | $235.00 | $245.00 |
| Joe Vruwink | Baird | Raises | Outperform | $255.00 | $251.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veeva Systems. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veeva Systems compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Veeva Systems's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Veeva Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Veeva Systems analyst ratings.
About Veeva Systems
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Breaking Down Veeva Systems's Financial Performance
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Veeva Systems's remarkable performance in 3 months is evident. As of 30 April, 2024, the company achieved an impressive revenue growth rate of 23.56%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Veeva Systems's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.86% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.39%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Veeva Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.67% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Veeva Systems's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
